Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Akebia Therapeutics (NQ: AKBA )

3.050 USD -0.120 (-3.79%)
Official Closing Price Updated: 6:50 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Akebia Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief... 
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase... 
From PR Newswire
Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief... 
From PR Newswire
Peek Under The Hood: IEIH Has 17% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
3 Top Penny Stocks On Robinhood To Buy Under $3.50
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth
Virtual Panel of Nephrology Care Professionals to Share Insights and Experiences Managing Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis 
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an... 
From PR Newswire
Interesting AKBA Put And Call Options For July 2021
Investors in Akebia Therapeutics Inc (AKBA) saw new options become available this week, for the July 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay,... 
Tags Stocks
From Market News Video
Top Penny Stocks To Watch Today; 4 With 75%-233% Price Targets
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper... 
From PR Newswire
68 Biggest Movers From Yesterday
Gainers Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) gained 157.9% to close at $49.00 after the company priced its IPO at $19 per ... 
Tags MDGS Top Gainers Information Technology
From Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Naked Brand Group Limited (NASDAQ: NAKD) shares jumped 77.7% to $0.2302 after jumping around 47% on Wednesday. Phoenix ... 
Tags FIII CIIC FENG
From Benzinga
34 Stocks Moving in Thursday's Pre-Market Session
Gainers Hudson Capital Inc. (NASDAQ: HUSN) shares rose 44.2% to $3.23 in pre-market trading. Hudson Capital, on Monday, said it ... 
Tags AKBA GPRO Markets
From Benzinga
5 Best Penny Stocks Today If Biotech Stocks Are Your Focus
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's... 
From PR Newswire
Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most ... 
Tags Greenlight Capital MSI BMY
From Benzinga
Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a manuscript... 
From PR Newswire
Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates
- Presented positive global Phase 3 data for vadadustat from the INNO2VATE program for the treatment of anemia due to chronic kidney disease in adult patients on dialysis at ASN Kidney Week 
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase an... 
From PR Newswire
Stocks That Hit 52-Week Lows On Friday
Friday's morning session saw 24 companies set new 52-week lows. Significant Points: Walgreens Boots Alliance ... 
Tags Trading Ideas SNDL JAGX
From Benzinga
The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags BCDA UTHR AXGN
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
Before 10 a.m. ET Thursday, 104 stocks made new 52-week lows. Highlights: Wells Fargo (NYSE: WFC) was the largest ... 
Tags SFL PDM NRBO
From Benzinga
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags OPK ZSAN MRK
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning trading, 129 companies set new 52-week lows. Areas of Interest: The largest company in terms of ... 
Tags SEAC DBVT HAPP
From Benzinga
52 Biggest Movers From Yesterday
Gainers Scholar Rock Holding Corporation (NASDAQ: SRRK) shares jumped 118.8% to close at $30.02 on Tuesday after the company ... 
Tags CHGG TC KBSF
From Benzinga
Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results... 
From PR Newswire
Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session
- As previously announced, PRO2TECT data show vadadustat achieved primary and key secondary efficacy endpoints in each study, but did not meet the primary safety endpoint 
From PR Newswire
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags IBB Trading Ideas BIO
From Benzinga
5 Penny Stocks To Watch After Gilead Sciences’ Big Remdesivir News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Pati
- INNO2VATE data presented at American Society of Nephrology Kidney Week 2020 Reimagined 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.